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Summary The comparative nephrotoxicity of i.v. cisplatin, i.v. carboplatin and six p.o. ammine/amine Pt(IV)
dicarboxylates was studied in rodents following single MTD treatments. In mice, i.v. cisplatin caused
proteinuria (1 g '-l), glycosuria (16.7 mM) and decreased GFR at 4 days, and histological kidney damage with
onset at 6 days. In contrast, mice treated with i.v. carboplatin or p.o. ammine/amine Pt(IV) dicarboxylates had
urinary glucose, urinary protein, GFR and kidney histology within the control range. In rats, i.v. cisplatin
caused 5-fold elevations in plasma creatinine (188 ± 33jLM) and urea (30.4 ± 8.9 mM), a 10-fold fall in
creatinine clearance (0.54 ± 0.31 ml min-' kg-'), a 25-fold elevation in urine/plasma glucose concentration
ratio (3.28 ± 0.17), a 20% increase in kidney weight (7.9 ± 0.56 mg gm-' body weight) and extensive histo-
logical damage 4 days after treatment. In contrast, i.v. carboplatin and p.o. JM216 (the lead compound of this
series) caused neither abnormalities in renal function nor histological damage in rats. The nephrotoxicity of
single MTD treatments of p.o. ammine/amine Pt(IV) dicarboxylate complexes appears less than i.v. cisplatin
and comparable to i.v. carboplatin.
The discovery of cisplatin is arguably one of the most impor-
tant advances in cancer treatment of recent decades. The
clinical use of this drug is limited by severe toxicity, notably,
nephrotoxicity, neurotoxicity and emesis (Loehrer & Ein-
horn, 1984). Nephrotoxicity was dose-limiting during phase I
studies ofcisplatin (Rossof et al., 1972; DeConti et al., 1973).
It is clinically manifest by reversible asymptomatic elevation
of plasma urea and creatinine, occasional cases of frank
acute renal failure necessitating dialysis, cumulative and per-
manent reductions in GFR (Daugaard et al., 1988b), acute
and chronic tubular injury (characterised by reduced prox-
imal tubular salt and water reabsorption, magnesium was-
ting, normoglycaemic glycosuria, proteinuria, albuminuria,
amino aciduria, and acute enzymuria (Daugaard et al.,
1988a)), and, acute and chronic histological changes (Gonza-
lez-Vitale et al., 1977). The co-administration of intravenous
fluid, mannitol, and hypertonic saline in conjunction with
cisplatin has, at least partially, reduced the nephrotoxicity of
this compound and these prophylactic measures are now
widely used (Al-Sarraf et al., 1982). The development of
carboplatin has also reduced the nephrotoxicity of Pt-based
chemotherapy since this compound causes less kidney
damage than cisplatin and can be given safely without con-
comitant i.v. hydration (Calvert et al., 1982). Unlike cis-
platin, the tolerability of carboplatin is such that it can be
administered as outpatient treatment, however, both cisplatin
and carboplatin are intravenous preparations.
The ammine/amine Pt(IV) dicarboxylate class of Pt com-
plex are promising with regard to their in vitro activity
against human ovarian carcinoma cell lines both sensitive
and resistant to cisplatin (Kelland et al., 1992), and their
bioavailability after oral administration in mice (Harrap et
al., 1991). An oral Pt preparation could potentially improve
the quality of life of patients, reduce inpatient hospital costs
and facilitate studies of schedule-dependency. However, the
need to modulate the nephrotoxicity of an oral preparation
would negate many of the advantages of oral administration
since hydration is usually given in hospital and by the i.v.
route. In this study we have compared the nephrotoxicity of
six p.o. ammine/amine Pt(IV) dicarboxylates in rodents.
Cisplatin and carboplatin were used as positive and negative
controls since cisplatin is a known nephrotoxin while carbo-
platin causes relatively less kidney damage both clinically
(Calvert et al., 1982) and in experimental models (Harrap et
al., 1980). In vivo models were used because of the potential
for metabolism of ammine/amine Pt(IV) dicarboxylates and
difficulties simulating this in vitro. '4C-inulin clearance, his-
tology and renal tubular function were measured as these
have been reported as sensitive tests for cytotoxic drug-
induced kidney damage in rodents (Goldstein et al., 1986;
Jodrell et al., 1991). Six p.o. ammine/amine Pt(IV) dicar-
boxylates were studied in the mouse while more detailed
studies of the oral phase I agent (p.o. JM216) were under-
taken in the rat.
Materials and methods
Pt complexes (Table I)
Pt complexes were synthesised and supplied by the Johnson
Matthey Technology Centre, Reading, Berkshire, UK.
Drug administration
Female Balb c- mice and female Wistar rats were used in all
experiments. Cisplatin was dissolved in sterile 0.9% sodium
chloride (w/v) and carboplatin in sterile 5% dextrose (w/v)
by sonication and both were given intravenously (injection
volume, 10 mg kg') via the lateral tail vein. Transient local
(rats) or whole body (mice) hyperthermia (,<40'C) of less
than 3 min duration was used to facilitate injections in both
i.v. control and i.v. treatment groups. Ammine/amine Pt(IV)
dicarboxylates were suspended in arachis oil by sonication
and given by oral gavage (injection volume, 10 ml kg-').
Treatments were given as single maximum tolerated doses.
The MTDs for i.v. cisplatin (mice, 7 mg kg-'; rats, 6.5 mg
kg-') and i.v. carboplatin (mice, 120 mg kg-'; rats, 60 mg
kg-') were as previously described (Siddik et al., 1986). The
MTDs for p.o. ammine/amine Pt(IV) dicarboxylates were
determined in dose-finding experiments in which treatments
were given at a range of doses and a daily record of body
weight and signs of drug-induced toxicity were made. Any
animals in distress were immediately and painlessly killed by
cervical dislocation. The MTDs (the maximum non-lethal
dose) were as follows: mice; p.o. JM221 130mg kg-'; p.o.
JM256 150mg kg-', p.o. JM216 200mg kg-' p.o. JM225
180 mg kg-', p.o. JM291 320 mg kg-', p.o. JM251 170 mg
kg-': rats; p.o. JM216 150mg kg-'. In subsequent experi-
ments these doses caused lethality in A 1 animal/
experimental group and reversible body weight loss. In a
multiple-dose study, mice were treated weekly for 4 con-
secutive weeks with doses equivalent to 50% of the single
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Table I Chemical structures of ammine/amine Pt(IV) dicarboxylate
complexes
OCOR,
H3NI- I R2
Pt
RH2NJ -R2
OCOR,
R RI R2
JM221 c-C6H,, C3H7 C1
JM256 c-C6H,, NHC2H5 Cl
JM216 c-C6H,I CH3 CI
JM225 c-C5H9 CH3 Cl
JM251 c-C6H,, H C1
JM291 c-C6HI CH3 ococooa
abidentate.
dose MTD/week. Animals receiving either i.v. or p.o. treat-
ment were fasted for 18 h prior to drug administration dur-
ing which time free access to drinking water was maintained.
Treatment was given between 0930 and 1200 h.
Sample collection
Detailed studies of nephrotoxicity were undertaken 4 days
after single MTD treatments since this is when the nephro-
toxicity of cisplatin and other Pt complexes are maximal in
the rat (Goldstein et al., 1981; Ward et al., 1976) and when
cisplatin-induced disturbances in renal function are apparent
in the mouse (Jodrell et al., 1991). Additional time-course
studies of p.o. ammine/amine Pt(IV) dicarboxylate treatment
were undertaken in both mice, when kidneys were examined
histologically at time-points ranging from 2 h to 10 days, and
rats, when plasma urea was measured from 24 h to 12 days
after treatment with p.o. JM216. Blood was collected under
terminal halothane anaesthesia from an axillary incision into
tubes containing heparin (10 units), except during time-
course studies in the rat when blood (0.25 ml) was collected
by venepuncture from the tail vein into microfuge tubes
containing heparin (5 units). Blood was immediately centri-
fuged and a plasma sample set aside for analysis. Urine was
collected for 24 h from 72 to 96 h from animals (both mice
and rats) housed individually in metabolism cages. Urine was
kept refrigerated (4°C) during the collection period. Urine
collections from mice were pooled (six mice/treatment group)
while collections from individual rats were stored (-20C)
and analysed individually.
Renalfunction
Protein and glucose concentrations in pooled 24 h urine col-
lections from mice (six mice/group) taken from 72 to 96 h
were read off urinary dip sticks (BM-Test-5L, Boehringer
Mannhaim, Bracknell, Berkshire, UK). In a separate experi-
ment, GFR was determined in mice 4 days after treatment by
the '4C-inulin clearance technique as previously described
(Jodrell et al., 1991). In a time-course study, mice were
sacrificed at time-points ranging from 2 h to 10 days follow-
ing treatment and the kidneys were removed and examined
histologically. In a multiple-dose study, mice were killed 2
days after completing four consecutive weekly treatments and
the kidneys were removed for histological examination. Spec-
imens were prepared for histological examination by fixation
in modified methacarn (methanol 600 ml, inhibisol 300 ml,
acetic acid 100 ml) for 24 h, dehydration with ethanol,
embedding in paraffin wax and staining with haematoxylin
and eosin. In rats, plasma and urine samples were analysed
for urea, creatinine and glucose concentrations using a Beck-
man Synchron AS8 automated analyser. For creatinine
clearance determinations in rats, urine was collected for 24 h
from 72 to 96 h and the urinary volume and urinary
creatinine concentration recorded. Rats were sacrificed
immediately after the urine collection (96 h) and a plasma
sample taken for plasma creatinine determination. The
creatinine clearance was derived by dividing the product of
the urinary excretion rate (ml min 1) and urinary creatinine
concentration by the plasma creatinine concentration.
Creatinine clearance was expressed as a function of body
weight. Urinary N-acetyl-p-D-glucosaminidase (NAG) and
leucine aminopeptidase (LAP) activity of rat urine collected
from 72 to 96 h after treatment was determined using
fluorometric and colorimetric methods as previously des-
cribed (Jones et al., 1980). Urinary enzyme activity was
expressed as a function of urinary creatinine concentration.
The significance of differences was tested by the t-test (Tal-
larida & Murray, 1987).
Results
Mice (Table II)
Urine from control mice treated with i.v. drug vehicle alone
(0.9% sodium chloride, 10 mlkg-') scored negative for both
protein and glucose. Similarly, urine from mice treated with
i.v. carboplatin showed no glucose or protein. In contrast,
collections made from cisplatin-treated mice were + + for
protein (1 g1`) and + + + for glucose (16.7 mM). Urine
from control mice treated with p.o. drug vehicle alone
(arachis oil, 10 ml kg-') showed mild proteinuria (+,
0.3 g1`) and glycosuria ( +, 2.8 mM), while collections from
mice treated with p.o. ammine/amine Pt(IV) dicarboxylates
had similar levels of protein (+, 0.3 g1) but less glucose
(0.OmM) than the control group.
'4C-inulin clearance was estimated 4 days after treatment.
Relative to control mice treated with i.v. drug vehicle alone,
i.v. cisplatin induced a 45% reduction in '4C-inulin clearance,
whereas no significant reduction was seen following i.v. car-
boplatin treatment ('4C-inulin clearance, (ml min-' kg-1): i.v.
control, 17.7 + 1.1; i.v. cisplatin, 9.8 ± 4.2, P<0.001; i.v.
carboplatin, 16.7 + 1.7; P>0.1). In comparison to control
mice treated with p.o. drug vehicle, those given p.o. JM216
or p.o. JM221 at the MTD had similar or slightly higher
'4C-inulin clearances ('4C-inulin clearance (ml min ' kg-1):
p.o. control, 16.2 + 0.7; p.o. JM216, 17.7 ± 1.6, 0.01 <
P<0.05; p.o. JM221, 16.4+1.1, P>0.1). At a dose above
the MTD, JM221 (210 mgM-2) induced a small reduction
(12%) in '4C-inulin clearance (14.2 ± 1.6 ml min' kg-';
P< 0.001).
Kidneys were examined histologically over a time-course
from 2 h to 10 days following single MTD treatments. Renal
tubular epithelial necrosis was present following i.v. cisplatin
treatment at 6 and 10 days. No abnormality was found
following i.v. carboplatin treatment. Following p.o. JM291,
an abnormality consisting of a cortical fatty change, without
necrosis, was recorded at day 6 with resolution at day 10.
Oral treatment with other members of the series of ammine/
amine Pt(IV) dicarboxylates caused no histological kidney
damage. In a multiple-dose experiment, kidneys were
examined histologically after four consecutive weekly doses.
Renal tubular necrosis was seen following i.v. cisplatin, but
no abnormality was found following multiple doses of i.v.
carboplatin, p.o. JM216, p.o. JM225, p.o. JM291 and p.o.
JM251. Plasma urea and creatinine concentrations were
measured over a time-course and were not elevated after
treatment with i.v. cisplatin or any other Pt complex.
Rats (Figure I and Table III)
Following an MTD of i.v. cisplatin, elevations in plasma
urea were first seen at 48 h, maximal at 5 days and had
recovered, albeit incompletely, by 12 days (Figure 1). In
contrast, no elevation in plasma urea was seen following i.v.
carboplatin or p.o. JM216 at time points ranging from 24 h
to 12 days. In more detailed studies at 4 days after treatment998 M.J. MCKEAGE et al.
Table II Proteinuria, glycosuria, GFR and kidney histology following single MTD treatments of Pt complexes in mice
Dose Proteinuria Glycosuria GFR (day 4)b Histology
Treatment (mgkg-') (day 4)a (day 4)a (mlmin-'kg') (% change) (2h, 2 days, 6 days, 10 days)
i.v. control 0.9% NaCl 0 0 17.7 ± 1.1 normal
i.v. cisplatin 7 + + + + + 9.8 ± 4.2 - 45%C proximal tubular necrosis
i.v. carboplatin 120 0 0 16.7 1.7 - 6% normal
p.o. control arachis oil + + 16.2 ± 0.7 normal
p.o. JM221 130 + 0 16.4± 1.1 + 1% normal
210 14.2 1.6 -12%C
p.o. JM256 150 + 0 N.D. normal
p.o. JM216 200 + 0 17.7 ± 1.6 + 9% normal
p.o. JM225 180 + 0 N.D. normal
p.o. JM291 320 + 0 N.D. transient cortical fatty change
p.o. JM251 170 + 0 N.D. - normal
aPooled urine from six mice collected 72-96 h after treatment, proteinuria (+ 0.3 g 1 ', + + I g 1 ', + + + 5 g 1-), glycosuria
(+ 2.8 mm, + + 5.6 mm, +++ 16.7mM). bMean ± standard deviation, n= 3-8. cSignificant reduction compared to control,
P<0.001. N.D., not done.
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Figure 1 Time-course of plasma urea concentrations following single MTD doses of i.v. cisplatin, i.v. carboplatin and p.o. JM216
in rats (mean ± standard deviation, n = 3, *P<0.05).
Table III Plasma urea, plasma creatinine, creatinine clearance, urine/plasma glucose ratio and kidney
weight 4days after single MTD treatments ofi.v. cisplatin, i.v. carboplatin and p.o. JM216 in female Wistar
rats (mean ± standard deviation)
Plasma Plasma Creatinine Urine/plasma Kidney
urea creatinine clearance glucose weight
(mM) (fM) (mlmin-' kg-') ratio (mgg-' body wt)
control 6.2 1.1 46 ± 20 5.9 ± 2.8 0.13 ± 0.04 6.6 ± 0.53
(n = 7)
i.v. cisplatin 30.4 ± 8.9a 188 ± 33a 0.54 ± 0.31a 3.28 ± 0.17a 7.9 ± 0.56b
(n = 3)
i.v. carboplatin 5.5 + 0.5 36.7 ± 3.8 5.8 ± 1.3 0.14 ± 0.12 6.7 ± 0.2
(n = 3)
p.o. JM216 4.4 ± 0.7 35.3 ± 4.5 5.5 ± 0.83 0.16 ± 0.13 7.1 ± 0.4
(n = 3)
ap<0001;bo.00 <P<0.02.
(Table III), rats receiving i.v. cisplatin showed 5-fold eleva-
tions in plasma urea and creatinine (both P<0.001), a 10-
fold reduction in creatinine clearance (0.01 <P<0.02), a
25-fold elevation in urine/plasma glucose concentration ratio
(P<0.001) and a 20% increase in kidney weight (0.02>
P>0.01). By comparison renal function in rats treated with
i.v. carboplatin or p.o. JM216 was normal. At 4 days rats
treated with i.v. cisplatin showed histological changes consis-
tent with drug-induced injury, i.e. gross dilatation of the
renal tubules, medullary tubular cast formation and necrosis
of the renal tubular epithelium as manifest by pyknotic
change, clearing of nuclear chromatin and cellular sloughing
into the tubular lumen. In contrast, the histological
appearances of rat kidney following i.v. carboplatin or p.o.
JM216 treatment were within normal limits. Urinary N-
acetyl-p-glucosaminidase (NAG) activity, urinary leucine
aminopeptidase (LAP) activity and urinary output 72 to 96 h
following treatment were similar in control and treatment
groups.
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Discussion
We have studied the nephrotoxicity of a series of six p.o.
ammine/amine Pt(IV) dicarboxylate complexes in rodents
with variations in chemical structure at the (i) axial
dicarboxylate (formato, acetato, butyrato or ethylcarbamate
substituents), (ii) amine (cyclopentylamine or cyclohexyl-
amine substituents), and (iii) leaving group (dichloro of
oxalato substituents) positions. These compounds have been
identified as potential candidates for clinical testing as orally
active Pt-based drugs (Harrap et al., 1991).
These studies of nephrotoxicity in rodents included i.v.
cisplatin and i.v. carboplatin as controls. The effects of i.v.
cisplatin were similar to those previously described (Harrap
et al., 1980; Jodrell et al., 1991; Ward et al., 1976) in that this
agent caused proteinuria, glycosuria, reduced GFR and
histological kidney damage in the mouse, and elevated
plasma creatinine, elevated plasma urea, reduced creatinine
clearance, urinary glucose wasting, increased kidney weight
and renal histological damage in the rat. By comparison, i.v.
carboplatin effected neither renal function nor kidney his-
tology in either species. These findings concur with their
relative clinical nephrotoxicity since cisplatin can cause severe
and irreversible damage to renal function in man (Daugaard
et al., 1988) while the toxicity of carboplatin is confined to
the reductions in GFR after high-dose therapy (Gore et al.,
1987) and the possibility of cumulative reductions in GFR in
some patient groups (Sleijfer et al., 1989; Mason et al., 1990).
In mice, single MTD treatments of six p.o. ammine/amine
Pt(IV) dicarboxylates caused neither proteinuria, glycosuria
nor major histological changes. Transient cortical fatty
change, without necrosis, was recorded following treatment
with one oral compound (JM291). GFR estimates in control
mice were similar to reported values (Jodrell et al., 1991) and
neither p.o. JM216 nor p.o. JM221 treatment at the MTD
caused reductions in this parameter. Above the MTD, p.o.
JM221 caused a small reduction in GFR, possibly in keeping
with reports of reductions in GFR during high-dose carbo-
platin therapy (Gore et al., 1987). In rats, the time-course of
elevated plasma urea following i.v. cisplatin treatment was
consistent with previous descriptions (Ward et al., 1976),
however, plasma urea was normal following treatment with
the oral phase I candidate (p.o. JM216) at time points rang-
ing from 24 h to 10 days. Creatinine clearance values in
control rats were similar to reference values (Altman & Ditt-
mer, 1974) and unchanged 4 days following p.o. JM216,
contrasting with the 10-fold reduction in creatinine clearance
following i.v. cisplatin. Urinary glucose wasting and his-
tological kidney damage in the rat was seen only with i.v.
cisplatin and not with p.o. JM216. These findings suggest
that single dose treatment at the MTD with p.o. ammine/
amine Pt(IV) dicarboxylates is non-toxic to the kidney in
rodents.
The renal effects of multiple dosing was studied and
neither p.o. JM216, p.o. JM225, p.o. JM291, nor p.o. JM251
given as weekly doses for 4 weeks caused histological kidney
damage in the mosue. Histological changes are amongst the
most sensitive manifestations of cytotoxic drug-induced
kidney damage in this species (Jodrell et al., 1991), however,
the lack of cumulative damage of p.o. ammine/amine Pt(IV)
dicarboxylates studies has not been confirmed by studies of
renal function to date. In mice, following single doses of i.v.
cisplatin, plasma creatinine and urea were within the control
range. This is consistent with previous suggestions of these
being of poor utility for screening purposes because they are
insensitive manifestations of Pt-induced kidney damage, both
in this species (Jodrell et al., 1991) and in man (Daugaard et
al., 1988b). Similarly in rats, we found neither urinary NAG
nor LAP activity elevated following cisplatin treatment.
In conclusion, this series of p.o. ammine/amine Pt(IV)
dicarboxylates are not toxic to the kidney in rodents at
maximum tolerated doses and on this basis are suitable for
development as oral Pt outpatient therapy. Their lack of
nephrotoxicity was comparable to i.v. carboplatin suggesting
that the co-administration of i.v. hydration, such as is neces-
sary with i.v. cisplatin, may not be required.
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Abbreviations: cisplatin, cis-diamminedichloroplatinum(II); carbopla-
tin, cis-diamminecyclobutanedicarboxylatoplatinum(II); GFR, glom-
erular filtration rate; h, hour; i.v., intravenously administered; p.o.,
orally administered; MTD, maximum tolerated dose; Pt, platinum.
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